Gilead Sciences (GILD) Holder Putnam Investments Has Trimmed Its Stake by $60.00 Million; Healthinvest Partners Ab Trimmed Anthem (ANTM) Stake by $9.65 Million; Stock Declined

May 25, 2018 - By Marie Mckinney

Gilead Sciences, Inc. (NASDAQ:GILD) Logo

Anders Hallberg decreased its stake in Anthem Inc (ANTM) by 77.72% based on its latest 2017Q4 regulatory filing with the SEC. Healthinvest Partners Ab sold 42,900 shares as the company’s stock declined 2.73% with the market. The hedge fund run by Anders Hallberg held 12,300 shares of the health care company at the end of 2017Q4, valued at $2.77 million, down from 55,200 at the end of the previous reported quarter. Healthinvest Partners Ab who had been investing in Anthem Inc for a number of months, seems to be less bullish one the $58.85B market cap company. The stock decreased 0.62% or $1.44 during the last trading session, reaching $230.62. About 678,364 shares traded. Anthem, Inc. (NYSE:ANTM) has risen 35.30% since May 25, 2017 and is uptrending. It has outperformed by 23.75% the S&P500.

Putnam Investments Llc decreased its stake in Gilead Sciences Inc (GILD) by 18.85% based on its latest 2017Q4 regulatory filing with the SEC. Putnam Investments Llc sold 845,105 shares as the company’s stock rose 1.93% while stock markets declined. The institutional investor held 3.64 million shares of the health care company at the end of 2017Q4, valued at $260.61 million, down from 4.48M at the end of the previous reported quarter. Putnam Investments Llc who had been investing in Gilead Sciences Inc for a number of months, seems to be less bullish one the $87.81 billion market cap company. The stock decreased 0.94% or $0.64 during the last trading session, reaching $67.53. About 4.35 million shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has risen 9.79% since May 25, 2017 and is uptrending. It has underperformed by 1.76% the S&P500.

More notable recent Gilead Sciences, Inc. (NASDAQ:GILD) news were published by: Seekingalpha.com which released: “Gilead Sciences (GILD) Presents at Bank of America Merrill Lynch 2018 Healthcare Conference (Transcript)” on May 16, 2018, also Seekingalpha.com with their article: “Gilead: I’m Thankful That I Sold” published on May 07, 2018, Nasdaq.com published: “3 Biotechs on the FDA’s Naughty List That Should Be on Investors’ Buy Lists” on May 22, 2018. More interesting news about Gilead Sciences, Inc. (NASDAQ:GILD) were released by: Seekingalpha.com and their article: “Gilead: Where’s The Next Catalyst?” published on May 18, 2018 as well as Seekingalpha.com‘s news article titled: “Gilead: What A Disaster” with publication date: May 08, 2018.

Since January 2, 2018, it had 0 buys, and 22 sales for $44.80 million activity. The insider Cogan John Francis sold 5,833 shares worth $440,741. On Thursday, February 1 the insider Alton Gregg H sold $2.09 million. On Wednesday, February 21 the insider Washington Robin L sold $401,566. The insider Meyers James R sold $8.02M. 60,000 shares valued at $4.68M were sold by WILSON GAYLE E on Friday, February 9.

Analysts await Gilead Sciences, Inc. (NASDAQ:GILD) to report earnings on July, 25. They expect $1.43 EPS, down 43.03% or $1.08 from last year’s $2.51 per share. GILD’s profit will be $1.86B for 11.81 P/E if the $1.43 EPS becomes a reality. After $1.37 actual EPS reported by Gilead Sciences, Inc. for the previous quarter, Wall Street now forecasts 4.38% EPS growth.

Investors sentiment decreased to 0.8 in 2017 Q4. Its down 0.23, from 1.03 in 2017Q3. It turned negative, as 95 investors sold GILD shares while 545 reduced holdings. 104 funds opened positions while 411 raised stakes. 972.68 million shares or 1.57% more from 957.62 million shares in 2017Q3 were reported. Welch And Forbes Ltd Liability Com owns 157,596 shares. Geode Capital Ltd owns 15.85M shares. Ci Investments stated it has 1.47% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Trust Department Mb State Bank N A accumulated 67,531 shares. 1,860 were accumulated by Mitsubishi Ufj. Aureus Asset Mgmt Lc invested in 4,832 shares. Salem Investment Counselors has 71,667 shares for 0.56% of their portfolio. Private Advisor Group Ltd Limited Liability Company has 35,891 shares for 0.11% of their portfolio. Pacific Heights Asset Mngmt Limited Liability Com has 0.75% invested in Gilead Sciences, Inc. (NASDAQ:GILD) for 107,000 shares. Private Harbour Investment Mgmt And Counsel Ltd Co owns 8,070 shares or 0.5% of their US portfolio. Sentinel Trust Lba accumulated 62,970 shares or 0.94% of the stock. Hermes Limited invested 0.02% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Point72 Asia (Hong Kong) reported 11 shares. Robecosam Ag reported 130,570 shares or 0.62% of all its holdings. 29,923 are owned by Amg Natl Tru Bank & Trust.

Putnam Investments Llc, which manages about $89.35B and $44.83 billion US Long portfolio, upped its stake in Yum! Brands Inc (NYSE:YUM) by 4,766 shares to 183,559 shares, valued at $14.98M in 2017Q4, according to the filing. It also increased its holding in Berry Global Group Inc (NYSE:BERY) by 81,446 shares in the quarter, for a total of 242,012 shares, and has risen its stake in Agnc Investment Corp.

Among 30 analysts covering Gilead Sciences (NASDAQ:GILD), 21 have Buy rating, 0 Sell and 9 Hold. Therefore 70% are positive. Gilead Sciences had 130 analyst reports since July 29, 2015 according to SRatingsIntel. The rating was maintained by Piper Jaffray with “Overweight” on Wednesday, February 3. Maxim Group maintained Gilead Sciences, Inc. (NASDAQ:GILD) on Tuesday, May 30 with “Hold” rating. The rating was initiated by Standpoint Research with “Buy” on Wednesday, February 3. On Tuesday, July 11 the stock rating was reinitiated by Jefferies with “Hold”. Mizuho maintained the stock with “Buy” rating in Monday, February 5 report. The firm has “Neutral” rating by Bank of America given on Friday, January 15. The company was maintained on Wednesday, February 3 by RBC Capital Markets. Credit Suisse maintained it with “Hold” rating and $80.0 target in Wednesday, January 3 report. Robert W. Baird maintained the stock with “Buy” rating in Friday, September 15 report. RBC Capital Markets maintained Gilead Sciences, Inc. (NASDAQ:GILD) on Wednesday, February 7 with “Buy” rating.

Among 25 analysts covering Anthem Inc (NYSE:ANTM), 18 have Buy rating, 0 Sell and 7 Hold. Therefore 72% are positive. Anthem Inc had 81 analyst reports since July 27, 2015 according to SRatingsIntel. The stock of Anthem, Inc. (NYSE:ANTM) has “Outperform” rating given on Thursday, June 16 by Bernstein. The rating was downgraded by Sterne Agee CRT on Tuesday, May 24 to “Neutral”. The firm earned “Hold” rating on Tuesday, September 13 by Jefferies. The stock has “Buy” rating by Cantor Fitzgerald on Monday, November 6. As per Friday, October 13, the company rating was maintained by Jefferies. The rating was downgraded by Stifel Nicolaus to “Hold” on Wednesday, January 4. Bank of America maintained Anthem, Inc. (NYSE:ANTM) on Friday, November 17 with “Buy” rating. The stock of Anthem, Inc. (NYSE:ANTM) has “Outperform” rating given on Thursday, July 30 by Oppenheimer. The company was upgraded on Thursday, April 26 by JP Morgan. The rating was maintained by Jefferies on Wednesday, June 7 with “Hold”.

Analysts await Anthem, Inc. (NYSE:ANTM) to report earnings on July, 25. They expect $4.16 EPS, up 23.44% or $0.79 from last year’s $3.37 per share. ANTM’s profit will be $1.06 billion for 13.86 P/E if the $4.16 EPS becomes a reality. After $5.41 actual EPS reported by Anthem, Inc. for the previous quarter, Wall Street now forecasts -23.11% negative EPS growth.

Gilead Sciences, Inc. (NASDAQ:GILD) Institutional Positions Chart

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>